Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Nieuwe tool biedt inzicht in gevolgen borstkanker tot 14 jaar na diagnose
feb 2022 | Borstkanker